Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson's (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
Tremfya is a biologic medication administered via injections into a vein or under the skin to treat plaque psoriasis. It works by blocking interleukin-23, a protein involved in the overactive immune ...
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share. Tremfya ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
Johnson & Johnson's Immunology sales fell 12% in Q1 2026 after Stelara lost exclusivity. JNJ's Tremfya sales jumped 64% to $1.6B and could surpass $10B in peak-year sales. JNJ sees newly approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results